Oncotalks | Powered by Novartis

Kisqali Channel

In this section, which is only accesible for registered healthcare professionals, video interviews are available related to the treatment of advanced breast cancer patients with ribociclib. The latest data from scientific congresses (ASCO, ESMO, SABC) and interviews with medical experts, for example on therapy management

Considering outstanding PFS data in 1st Line of Kisqali+Fulvestrant, what would the most promising treatment combination in 1st Line be (CDK + AI or CDK + fulvestrant) ? How is this choice going to impact the treatment sequence strategy?

Considering outstanding PFS data in 1st Line of Kisqali+Fulvestrant, what would the most promising treatment combination in 1st Line be (CDK + AI or CDK + fulvestrant) ? How is this choice going to impact the treatment sequence strategy?

Dr. Cornelia Kolberg-Liedtke is commenting on "Considering outstanding PFS data in 1st Line of Kisqali+Fulvestrant, what would the most promising treatment combination in 1st Line be (CDK + AI or CDK + fulvestrant) ? How is this choice going to impact the treatment sequence strategy?"

Kisqali Channel

00:05:47

Comment on ESMO MCBS

Comment on ESMO MCBS

Professor Christian Singer is commenting on ESMO MCBS score of Kisqali.

Kisqali Channel

00:02:32

Can you describe more into depth the hormone resistant patient population included in M3 trial?

Can you describe more into depth the hormone resistant patient population included in M3 trial?

Professor Mario Campone is describing more into depth the hormone resistant patient population included in M3 trial.

Kisqali Channel

00:03:54

All CDK4/6 trials have OS results, can you comment on this?

All CDK4/6 trials have OS results, can you comment on this?

Dr. Konstantinos Papazisis is commenting on "All CDK trials have OS results."

Kisqali Channel

00:02:14

Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember?

Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember?

Professor Janice Walshe is discussing "Does the use of Kisqali delays time to chemotherapy (in M3 trial) ? And which numbers should we remember?"

Kisqali Channel

00:01:42

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?

Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?"

Kisqali Channel

00:02:25

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this?

Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor."

Kisqali Channel

00:02:23

All CDK4/6 have shown superior OS results?

All CDK4/6 have shown superior OS results?

Dr. Michelino De Laurentiis is speaking on "ALL CDK4/6 have shown superior OS results?"

Kisqali Channel

00:03:34

QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?

QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?

Dr. Elisabetta Munzone is speaking on "QoL improved or was maintained with Kisqali in M7 and M3, do we have any evidence of this?"

Kisqali Channel

00:02:49

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ?

Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?"

Kisqali Channel

00:03:08

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Is it easy to show overall survival in 1L HR+ HER2 – ABC?

Dr. Mattea Reinisch is talking on "Is it easy to show overall survival in 1L HR+ HER2 – ABC?"

Kisqali Channel

00:03:14

How clinical relevance is assessed in randomized clinical trials?

How clinical relevance is assessed in randomized clinical trials?

How clinical relevance is assessed in randomized clinical trials?

Kisqali Channel

00:05:42

«
1
2
3